NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jul 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INDERIDE LA 120/50 is a fixed-dose combination of propranolol (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic) in extended-release capsule form. It is indicated for hypertension management, leveraging dual mechanisms: propranolol reduces cardiac output and renin release, while hydrochlorothiazide promotes sodium and water excretion. This combination therapy targets patients requiring multi-agent blood pressure control.
LOE Approaching
This vintage 1985 product faces moderate competitive pressure (30% signal) and is approaching loss of exclusivity, signaling a defensive team posture focused on retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on INDERIDE LA offers limited growth-trajectory opportunities but strong exposure to mature-product management, generic competition dynamics, and payer negotiations. Professionals on this team typically develop expertise in cost-optimization, retention strategies, and regulatory compliance in a declining-revenue environment.
Brand ManagerField Sales Representative
Worked on INDERIDE LA 120/50 at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.